Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) and Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.
Earnings & Valuation
This table compares Nektar Therapeutics and Qualigen Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nektar Therapeutics | $55.23 million | 37.95 | -$164.08 million | ($8.42) | -7.37 |
| Qualigen Therapeutics | N/A | N/A | -$6.26 million | ($7.50) | -0.16 |
Profitability
This table compares Nektar Therapeutics and Qualigen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nektar Therapeutics | -284.18% | -85.40% | -39.99% |
| Qualigen Therapeutics | N/A | N/A | -202.16% |
Institutional & Insider Ownership
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Nektar Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Nektar Therapeutics and Qualigen Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nektar Therapeutics | 1 | 1 | 9 | 0 | 2.73 |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Nektar Therapeutics presently has a consensus price target of $149.63, indicating a potential upside of 141.21%. Given Nektar Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than Qualigen Therapeutics.
Summary
Nektar Therapeutics beats Qualigen Therapeutics on 8 of the 13 factors compared between the two stocks.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
